CAS 1182367-47-0: 2-Chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile

RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.

RAD 140 is a selective androgen receptor modulator (SARM), which is a type of synthetic compound designed to mimic the effects of anabolic steroids with reduced androgenic properties. Originating from pharmaceutical research, RAD 140 is engineered to selectively target androgen receptors in muscle and bone tissues, minimizing unwanted effects on other organs, such as the liver and prostate. RAD 140 exerts its action by binding to androgen receptors, thereby activating anabolic pathways that promote muscle growth and improve physical performance. Unlike traditional anabolic-androgenic steroids, RAD 140 aims to selectively stimulate anabolism without significant androgenic side effects. This specificity makes it a compelling subject for research, particularly in muscle wasting, osteoporosis, and hypogonadism scenarios. In scientific studies, RAD 140 has been explored for its potential to increase lean muscle mass, enhance strength, and improve metabolic rates. These characteristics present promising implications in both therapeutic and performance contexts. Ongoing research is crucial to fully understand its efficacy, safety profile, and potential applications in clinical settings. While preliminary findings are encouraging, thorough investigations are essential to establish long-term outcomes and regulatory considerations.

Applications RAD 140 is a potent, orally bio-available, and non-steroidal selective androgen receptor modulator (SARM). References Miller, C.P., et al.: ACS Med. Chem. Lett., 2, 124-129 (2011)